Health and wellness products company Herbalife (NYSE:HLF) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.4% year on year to $1.22 billion. Next quarter’s revenue guidance of $1.26 billion underwhelmed, coming in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.59 per share was 44.9% above analysts’ consensus estimates.
Is now the time to buy Herbalife? Find out in our full research report.
“As I transition into the role of CEO, I am committed to honoring Herbalife’s 45-year legacy of empowering our communities through health, wellness and a strong entrepreneurial opportunity," said Stephan Gratziani.
With the first products sold out of the trunk of the founder’s car, Herbalife (NYSE:HLF) today offers a portfolio of shakes, supplements, personal care products, and weight management programs to help customers reach their nutritional and fitness goals.
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years.
With $4.95 billion in revenue over the past 12 months, Herbalife carries some recognizable products but is a mid-sized consumer staples company. Its size could bring disadvantages compared to larger competitors benefiting from better brand awareness and economies of scale.
As you can see below, Herbalife’s revenue declined by 4.2% per year over the last three years as consumers bought less of its products.
This quarter, Herbalife missed Wall Street’s estimates and reported a rather uninspiring 3.4% year-on-year revenue decline, generating $1.22 billion of revenue. Company management is currently guiding for a 1.5% year-on-year decline in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 1.7% over the next 12 months. While this projection indicates its newer products will spur better top-line performance, it is still below the sector average.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
When analyzing revenue growth, we care most about organic revenue growth. This metric captures a business’s performance excluding one-time events such as mergers, acquisitions, and divestitures as well as foreign currency fluctuations.
The demand for Herbalife’s products has barely risen over the last eight quarters. On average, the company’s organic sales have been flat.
In the latest quarter, Herbalife’s organic sales rose by 1.4% year on year. This growth was an acceleration from its historical levels, which is always an encouraging sign.
We liked how Herbalife beat analysts’ EBITDA and EPS expectations this quarter. On the other hand, its EBITDA guidance for next quarter missed and its organic revenue fell short of Wall Street’s estimates. Overall, this quarter was mixed but still had some key positives. The market seemed to focus on the negatives, and the stock traded down 1.7% to $7.06 immediately after reporting.
So should you invest in Herbalife right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it’s free.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.